TOPLINE: Inotuzumab ozogamicin (IO), an anti‐CD22 antibody conjugated with calicheamicin, was well tolerated and demonstrated an overall response rate of 74% in adult patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (B-ALL) in a real-world study. METHODOLOGY: Researchers conducted a multicentre retrospective cohort study involving 73 adult patients (median age at IO initiation...
GET PAID FOR SHOPPING AT ALL YOUR FAVORITE STORES!
Sound too good to be true? Here’s the deal: Stores pay us a commission for sending you their way.
We share that with you as Cash Back. Everyone wins! SIGN UP FOR FREE!
.png)
COOL ROOM ENTERTAINMENT 10530 Campus Way South #1174 Largo, MD 20774
(916) 619-1308
teosmoot@gmail.com
Copyright © 2024 Cool Room Entertainment. All Rights Reserved
